Key result
Current and novel therapies for congestive heart failure, including ivabradine and sacubitril/valsartan, show promise but require further rigorous clinical trials to assess true effectiveness.
Population
Patients with congestive heart failure
Design
Review
Authors
Loading...
Urges caution against routine adoption of ivabradine or sacubitril/valsartan; leaves open their effectiveness pending rigorous trials.
This review highlights the current landscape of congestive heart failure treatments, emphasizing newly approved drugs and emerging therapies under research.
J.Momin et al. (2018) conducted a review in Congestive heart failure. Current and novel therapies (ivabradine, sacubitril/valsartan, gene therapy, stem cell therapy) was evaluated. Current and novel therapies for congestive heart failure, including ivabradine and sacubitril/valsartan, show promise but require further rigorous clinical trials to assess true effectiveness.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: